Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 17/20 | 0.81 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.59 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.59 |
| ▸ | BRD4 | O60885 | 1/20 | 0.59 |
| ▸ | TNF | P01375 | 1/20 | 0.59 |
| ▸ | IL1B | P01584 | 1/20 | 0.59 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.53 |
| ▸ | IKZF2 | Q9UKS7 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL476917 | 0.89 | CRBN (1.00) | CRBNDDB1IKZF3BRD4TNF | |
| SCHEMBL27097754 | 0.89 | CRBN (1.00) | CRBNDDB1IKZF3BRD4TNF | |
| SCHEMBL19556664 | 0.89 | CRBN (1.00) | CRBNDDB1IKZF3BRD4TNF | |
| SCHEMBL19556665 | 0.89 | CRBN (1.00) | CRBNDDB1IKZF3BRD4TNF | |
| SCHEMBL30995305 | 0.87 | CRBN (0.81) | CRBNDDB1IKZF3BRD4TNF | |
| SCHEMBL30122000 | 0.87 | CRBN (0.81) | CRBNDDB1IKZF3BRD4TNF | |
| SCHEMBL18270886 | 0.82 | CRBN (0.85) | CRBNDDB1IKZF3BRD4TNF | |
| SCHEMBL27925240 | 0.80 | CRBN (0.80) | CRBNDDB1IKZF3BRD4TNF | |
| SCHEMBL30458312 | 0.79 | CRBN (0.65) | CRBNDDB1 | |
| SCHEMBL30459200 | 0.79 | CRBN (0.69) | CRBNDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023104155-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | 标新生物医药科技(上海)有限公司 | 2023-06-15 | — | — | WO | claimed |
| WO-2023066350-A1 | CRBN E3 LIGASE LIGAND COMPOUND, PROTEIN DEGRADING AGENT DEVELOPED ON THE BASIS OF LIGAND COMPOUND, AND THEIR APPLICATIONS | 标新生物医药科技(上海)有限公司 | 2023-04-27 | — | — | WO | claimed |
| US-20260014133-A1 | SUBSTITUTED 3-(l-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE/2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-l,3-DIONE ANALOGS AS MODULATORS OF CEREBLON PROTEIN | ST JUDES CHIDRENS RES HOSPITAL INC (US) | 2026-01-15 | — | — | US | disclosed |
| EP-4466260-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca AB (SE) | 2024-11-27 | — | — | EP | disclosed |
| WO-2023139199-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023104155-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | 标新生物医药科技(上海)有限公司 | 2023-06-15 | — | — | WO | disclosed |
| WO-2023280237-A1 | SYNTHESIS AND APPLICATION OF PHOSPHATASE DEGRADER | 海创药业股份有限公司 | 2023-01-12 | — | — | WO | disclosed |
| WO-2022253283-A1 | PROTEIN KINASE DEGRADANT AND USE THEREOF | 中国科学院上海有机化学研究所 | 2022-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014133-A1 | SUBSTITUTED 3-(l-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE/2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-l,3-DIONE ANALOGS AS MODULATORS OF CEREBLON PROTEIN | CRBN, CDR2, CLNS1A | CRBN 1/4885DDB1 270/4885IKZF3 1067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.